Submitted:
28 November 2025
Posted:
01 December 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Methods
2.1. Data Source and Study Population
2.2. Data Processing
2.3. Statistical Analysis
2.3.1. Descriptive Statistics
2.3.2. Bivariate Analyses
Age and F13A1 Expression:
Sex and F13A1 Expression:
2.3.3. Multivariate Analyses
2.3.4. Age-Stratified Analysis
3. Results
3.1. Study Population Characteristics
3.2. Bivariate Analysis: Age and F13A1 Expression
3.3. Bivariate Analysis: Sex and F13A1 Expression

3.4. Multivariate Analysis: Age and Sex as Predictors
| Predictor | Model 2 Coefficient | SE | Model 3 Coefficient | SE |
|---|---|---|---|---|
| Intercept | 6.796 | 0.563 | 7.181 | 0.621 |
| Age | 0.0255 | 0.007 | 0.0189 | 0.009 |
| Sex (Male) | 0.307 | 0.876 | ||
| Age × Sex | — | — | 0.0264 | 0.016 |
Model 2: Main Effects Model
Model 3: Interaction Model
3.5. Age-Stratified Analysis
3.6. Regression Diagnostics

4. Discussion
4.1. Principal Findings
4.2. Biological Interpretation
Compensatory Response to Aging:
Age-Related Inflammatory Milieu:
Altered Regenerative Capacity:
Fibrotic Tendency:
4.3. Absence of Sex Effects
4.4. Comparison with Previous Literature
4.5. Clinical Implications
4.6. Methodological Considerations
4.7. Future Directions
- Functional Studies: Investigate whether F13A1 overexpression or knockdown affects MSC proliferation, differentiation, matrix interactions, or therapeutic potency.
- Protein Validation: Confirm age-related changes at the protein level using Western blotting, ELISA, or mass spectrometry approaches.
- Longitudinal Studies: Examine F13A1 expression changes within individuals over time to distinguish aging effects from inter-individual variation.
- Mechanistic Investigation: Elucidate transcriptional regulators and signaling pathways mediating age-related F13A1 upregulation.
- Tissue-Specific Analysis: Determine whether similar age-related patterns occur in MSCs from other tissue sources (adipose, umbilical cord) or in other cell types.
- Clinical Translation: Assess whether F13A1 expression levels predict clinical outcomes in MSC-based therapies.
5. Conclusion
Conflicts of Interest
References
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. [CrossRef]
- Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709–713. [CrossRef]
- Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6(6):1445–1451. [CrossRef]
- Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129(3):163–173. [CrossRef]
- Alves H, van Ginkel J, Groen N, et al. A mesenchymal stromal cell gene signature for donor age. PLoS One. 2012;7(8):e42908. [CrossRef]
- Board PG, Webb GC, McKee J, Ichinose A. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24→p25. Cytogenet Cell Genet. 1988;48(1):25–27. [CrossRef]
- Hethershaw EL, Cilia La Corte AL, Duval C, et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost. 2014;12(2):197–205. [CrossRef]
- Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105. [CrossRef]
- Austad SN, Fischer KE. Sex differences in lifespan. Cell Metab. 2016;23(6):1022–1033. [CrossRef]
- Geissler S, Textor M, Kühnisch J, et al. Functional comparison of chronological and in vitro aging: differential role of the cytoskeleton and mitochondria in mesenchymal stromal cells. PLoS One. 2012;7(12):e52700. [CrossRef]
- Carvalho MS, Alves L, Bogalho I, Cabral JMS, da Silva CL. Impact of donor age on the osteogenic supportive capacity of mesenchymal stromal cell-derived extracellular matrix. Front Cell Dev Biol. 2021;9:747521. [CrossRef]
- Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion. 2013;53(5):1120–1131. [CrossRef]
- Biswas A, Ivaskevicius V, Seitz R, Thomas A, Oldenburg J. An update of the mutation profile of Factor 13 A and B genes. Blood Rev. 2011;25(5):193–204. [CrossRef]




| Variable | All (N=61) | Female (n=45) | Male (n=16) |
|---|---|---|---|
| Age (years) | |||
| Mean ± SD | 55.2 ± 17.4 | 57.8 ± 17.0 | 48.0 ± 16.9 |
| Median | 59.0 | 61.0 | 44.0 |
| Range | 17–84 | 19–84 | 17–75 |
| F13A1 Expression (log2-normalized) | |||
| Mean ± SD | 8.202 ± 1.030 | 8.271 ± 0.998 | 8.008 ± 1.125 |
| Median | 8.332 | 8.336 | 8.315 |
| Range | 4.414–10.491 | 4.414–10.491 | 5.251–9.287 |
| Model | R2 | Adj. R2 | F-statistic | p-value |
|---|---|---|---|---|
| Model 1: Age only | 0.187 | 0.174 | 13.59 | |
| Model 2: Age + Sex | 0.187 | 0.159 | 6.68 | 0.002 |
| Model 3: Age + Sex + Age×Sex | 0.223 | 0.182 | 5.44 | 0.002 |
| Age Group | n | Mean ± SD | Range |
|---|---|---|---|
| <30 years | 7 | 7.043 ± 1.370 | 5.251–9.143 |
| 30–50 years | 15 | 8.075 ± 0.813 | 6.390–9.287 |
| 50–70 years | 26 | 8.382 ± 1.002 | 4.414–10.491 |
| >70 years | 13 | 8.613 ± 0.663 | 7.719–9.789 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).